People with persistent post-treatment Lyme disease (PTLD) may
benefit from controlled clinical use of psilocybin, according to researchers at
the Johns Hopkins School of Medicine.
In an open-label pilot study involving 20 PTLD patients, two guided
psilocybin sessions over 8 weeks led to marked reductions in PTLD symptom
burdens, improvements in quality of life, and better mental and physical
functioning. The treatments were without serious adverse effects, and the
benefits endured for 6 months following the second treatment session.
“PTLD
is a condition that is growing in prevalence, that results in substantial
detriment to patient quality of life, and is currently lacking accepted
treatments,” write Albert Garcia-Romeu and colleagues in their recent paper in Nature
Scientific Reports.
Written by Shree Nadkarni, MD, Contributing Writer
(This article was originally published on Undark. Read the original article.) In the 1960s, biophysicist Norman J. “Jeff” Holter commercialized a portable electrocardiogram — now known as a Holter monitor — which allowed patients with heart palpitations, a condition known as syncope (a medical term for fainting), or other cardiac issues to be monitored outside […]
A patient comes to me with a lab report showing a rise in creatinine, along with a chilling sentence her doctor told her: your kidneys are failing. She also has a two-page supplement protocol. By the time she is in my chair, this patient has been frightened for weeks. She’s also confused about what might […]
Pain
and chronic inflammation underlie many conditions that holistic practitioners
encounter every day — from joint degeneration and neuropathy to migraine,
menstrual disorders, and post-exercise recovery.
Yet
the dominant pharmaceutical toolkit remains constrained by adverse effects,
dependency risk, and an inability to address the underlying biology of
neuroinflammation.
This
webinar invites you to explore palmitoylethanolamide (PEA) –a well-researched,
endogenously produced lipid mediator that the human body already uses to
regulate pain and repair damaged tissue.
Specifically, we will focus on Levagen®+, Saanroo’s clinically-validated PEA formulation powered by patented LipiSperse® dispersion technology, which greatly improves absorption and bioavailability of PEA.
Chemist
Ramasamy V. Venkatesh will lay out the scientific basis for clinical use
of PEA, reviewing its multi-receptor mechanism — primarily through PPAR-α
activation, alongside indirect modulation of CB1 and CB2 receptors and
interactions with GPR55 and TRPV1. You’ll learn how this “parallel
endocannabinoid” signaling pathway makes PEA uniquely suited to address
both peripheral and central pain while avoiding psychoactive effects.
Dr. Venkatesh will also present a comprehensive review of the clinical research on Levagen®+ across multiple pain and inflammation applications. Highlights include randomized, double-blind, placebo-controlled trials showing Levagen®+’s efficacy for joint pain and stiffness, acute menstrual pain, migraine, and exercise-induced muscle damage.
You will gain a deep understanding of how to apply Levagen®+ in the care of diverse patient subgroups—not as a one-size-fits-all supplement, but as a precision tool that targets endocannabinoid-adjacent pathways involved in pain.
Ramasamy V. Venkatesh is a chemist with over 40 years of experience in the healthcare industry, specializing in pharmaceuticals and nutraceuticals. He is the founder and managing director of the Gencor Group worldwide. He has extensive international business experience in the pharmaceutical and nutraceutical sectors, having conducted business in more than 70 countries. His expertise covers R&D management, scientific reviews, product development, clinical trials, branding, and strategic partnerships, with a proven track record of successfully launching branded products globally in the nutraceutical market. Venkatesh serves on several advisory boards across the nutraceutical and pharmaceutical industries. In 2024, he received the Nutri Champion Award from NutraIngredients in 2024, for the significant impact his work has had on the dietary supplement industry. He is known for raising standards by using high-quality, clinically supported ingredients.
Venkatesh is highly respected by colleagues, clients, and the industry at large for his exceptional work ethic and selfless dedication. His commitment extends beyond his professional achievements, as he also actively promotes equal opportunities and empowers women in business and sports.
